Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 29%
Buy 21%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis is well-positioned for growth in the near- to medium-term with multiple upcoming catalysts, including initiation of Phase 3 trials and potential FDA approval for zanzalintinib in different tumor types. Despite missing in the NLM subset, the STELLAR-303 study supports the efficacy of zanzalintinib in combination with atezolizumab, and with strong demand for their current commercial portfolio, the company's future looks promising. It is estimated that Exelixis' revenue will increase by 32.4% in the next fiscal year and reach $2.71 billion in sales in 2025.

Bears say

Exelixis is facing several key risks that may impact its financial performance, including potential commercial risks with its lead drug Cabometyx, clinical trial risks with its pipeline candidates, generic erosion of existing franchises, and possible dilution risks from potential equity financings. In addition, the company operates in a highly competitive industry, which may limit its market share and impact its profitability. These factors, combined with the negative trends in its valuation and possible delays in regulatory approvals, contribute to a negative outlook on Exelixis's stock.

Exelixis (EXEL) has been analyzed by 14 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 21% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 14 analysts, Exelixis (EXEL) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.